ロード中...
TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study
This double-blind, randomized, placebo-controlled, sequential group, phase 1 study was designed to assess in healthy men, the safety, tolerability, pharmacokinetics, and translational pharmacodynamics of JNJ-39439335 (mavatrep), a transient receptor potential vanilloid subtype 1 antagonist; it was p...
保存先:
| 出版年: | Pain Rep |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5741288/ https://ncbi.nlm.nih.gov/pubmed/29392196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PR9.0000000000000576 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|